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ABSTRACT 
Heterozygous mutations in the splicing factor SF3B1 are frequently occurring in various cancers and drive tumor 
progression through the activation of cryptic splice sites in multiple genes. Recent studies moreover demonstrate 
a positive correlation between expression levels of wildtype SF3B1 and tumor malignancy, although the 
underlying mechanisms for this phenomenon remain elusive.  Here, we report that SF3B1 acts as a coactivator 
for hypoxia-inducible factor (HIF)1α through a splicing-independent mechanism. By directly interacting with 
HIF1α, SF3B1 augments HIF1α-HIF1β heterodimer binding to hypoxia response elements, and facilitates full 
transcriptional response of HIF target genes. We further validate the relevance of this mechanism for tumor 
progression, and show that monoallelic deletion of Sf3b1 impedes pancreatic cancer formation via HIF signaling. 
Altogether our work demonstrates a pivotal role of SF3B1 in the adaptation to hypoxia, suggesting a causal link 
between high SF3B1 levels and cancer aggressiveness. 
 





preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.10.376780doi: bioRxiv preprint 
 
MAIN  
SF3B1 is a core component of the U2 small nuclear ribonucleoprotein (snRNP) complex, involved in the 
recognition and selection of the branchpoint sequence in RNA splicing1. Missense mutations in this gene are 
frequently found in a number of different blood cancers (e. g. myelodysplastic syndrome, chronic lymphocytic 
leukemia) and solid tumors (e. g. breast and pancreatic cancers, uveal melanoma)2,3. They lead to aberrant 3’ 
splice site usage, resulting in the creation of novel isoforms and/or nonsense mediated decay of hundreds of 
genes4–7. For several of these splice isoforms, a direct tumor promoting function has been demonstrated (i.e. 
MAP3K7, PPP2R5A)8–10, confirming the proto-oncogenic role of SF3B1. Interestingly, recent tumor biomarker 
studies have also found a link between wildtype SF3B1 expression levels and tumor aggressiveness in 
endometrial-, prostate-, liver- and breast cancer, with higher expression being associated with adverse prognosis11–
14. Considering that in heart tissue SF3B1 overexpression is induced by hypoxia15, and that solid cancers are often 
poorly oxygenated16, we hypothesized that upregulation of wildtype SF3B1 in tumors facilitates adaptation to 
hypoxia. In this study we demonstrate that SF3B1 physically interacts with hypoxia inducible factor (HIF)1α to 
enable full transcriptional response to hypoxia, and show the importance of this mechanism for the progression 
of hypoxic cancers such as pancreatic ductal adenocarcinoma (PDAC). 
We previously observed that SF3B1 is regulated by HIF in ischemic heart conditions15. To assess if SF3B1 is also 
a HIF target gene in cancer, we first analyzed RNA sequencing (RNA-seq) data in four different solid cancers 
(PDAC, prostate cancer (PCA), hepatocellular carcinoma (HCC) and breast cancer (BRCA)). Supporting our 
assumption, we found a close correlation between the expression of SF3B1 and the two key components of HIF 
signaling, HIF1A and HIF1B in all four cancer types (Fig. 1A, B). Similar to the well-described HIF target gene 
CA917, we moreover observed a tendency for shorter survival in patients with higher SF3B1 expression (Fig. 1C). 
Due to the well-known hypoxic environment found in PDAC18, we focused on this cancer to further investigate 
the role of SF3B1 in HIF signaling.  In line with the hypothesis that SF3B1 is a HIF target, we found a strong 
correlation between the mean expression of 34 known HIF target genes and the expression of SF3B1 (p<0.001; 
Fig. 1D). Using a panel of patient-derived PDAC organoids, we furthermore discovered that SF3B1 expression is 
significantly upregulated upon experimental induction of hypoxia (Fig. 1E). In addition, expression of a 
constitutively active variant of HIF1α (HIF1α(Δ∆P)) in a PDAC cell line activated a wildtype SF3B1-promoter-
luciferase reporter, but not a mutant variant where the hypoxia-response element (HRE) of SF3B1-promoter was 
modified (Fig. 1F).  
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To next determine whether SF3B1 is not only a target of HIF signaling but also a regulator of HIF pathway 
activity, we manipulated SF3B1 expression levels in multiple human PDAC cell lines and patient-derived PDAC 
organoids via overexpression, siRNA-mediated knock-down, and monoallelic knockout (Suppl. Fig. 1A, 
B).  While SF3B1 overexpression caused an increase of VEGF-luciferase reporter activity in a concentration-
dependent manner (Fig. 1G, H), and an upregulation of known HIF target genes (Fig. 1I), reduction of SF3B1 
levels led to a significant downregulation of these target genes (Fig. 1I). Notably the strongest downregulation 
was observed for the prognostic biomarker CA9. Together, these data demonstrate that SF3B1 is a modulator of 
HIF signaling that is transcriptionally regulated by HIF activity. 
A study in breast cancer cell lines previously identified a panel of genes prone to intron retention upon SF3B1 
knock-down19. Interestingly, heterozygous loss of SF3B1 in PANC-1 cells did not lead to defective splicing in 
these genes (Suppl. Fig. 1C), indicating that SF3B1 modulates HIF signaling directly and not indirectly via the 
activation of cryptic splice sites in HIF pathway components. To test this hypothesis, we assessed whether SF3B1 
physically interacts with the core components of HIF signaling HIF1α and HIF1β. Immunoprecipitation assays 
indeed demonstrated that under hypoxic conditions SF3B1 binds to the HIF1α/HIF1β transcriptional complex 
(Fig. 2A, B). While depletion of SF3B1 by specific siRNAs did not interfere with binding between HIF1β and 
HIF1α (Fig. 2C, Suppl. Fig. 1D), siRNA-mediated depletion of HIF1α prevented co-immunoprecipitation of 
SF3B1 with HIF1β (Fig. 2D, Suppl. Fig. 1E). These data suggest that SF3B1 binds the HIF1α-HIF1β heterodimer 
via HIF1α, but that this binding is not critical for HIF1α-HIF1β heterodimer formation. To validate these findings, 
we produced recombinant SF3B1, HIF1α and HIF1β in vitro in Sf9 insect cells and mixed the purified proteins 
prior to analyzing their interactions in vitro. In this setting, SF3B1 co-immunoprecipitated with HIF1α and vice 
versa, irrespective whether HIF1β was present or not (Fig. 2E, F), but did not co-immunoprecipitate with HIF1β 
(Fig. 2F). We also aimed to identify the relevant domain in HIF1α that mediates binding to SF3B1 by producing 
a series of deletion mutants of HA-tagged HIF1α (Fig. 2G). Coimmunoprecipitation with endogenous SF3B1 
revealed that the bHLH-PAS-A-PAS-B domain is necessary and sufficient for SF3B1 complex formation (Fig. 
2H).  
Direct binding to the transcription factor HIF1α supports our assumption that SF3B1 modulates HIF signaling 
independent from its role in pre-mRNA splicing. To further investigate this hypothesis, we immunoprecipitated 
SF3B1 and HIF1α from hypoxic HEK293 cells, and immunoblotted for the presence of various core splicing 
components. Indeed, only SF3B1, but not HIF1α, immunoprecipitated with the U2snRNP splicing components 
SF3B4, SF3B2 and SF3B14 (Fig. 2I). As expected for a transcriptional co-factor of HIF1α, chromatin 
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immunoprecipitations (ChIP) experiments furthermore revealed that SF3B1 is bound to HREs of various HIF 
target genes under hypoxic conditions (Fig. 3A), and that this binding was abolished upon knockdown of HIF1α 
(Fig. 3B). Interestingly, when we next depleted SF3B1 by RNA interference, hypoxia-dependent association of 
HIF1α and HIF1β with HREs was strongly reduced on a number of HIF target gene promoters (Fig. 3C, D; Suppl. 
Fig. 1F, G). Together, these results suggest that the interaction of SF3B1 to HIF1α facilitates HIF1α-HIF1β 
heterodimer binding to HRE domains, enabling full transcriptional HIF response. Notably, we also assessed 
whether frequently occurring oncogenic mutations in SF3B1 could lead to enhanced binding with HIF1α, thereby 
improving the ability of cancer cells to adapt to hypoxia. However, when HIF1α was co-immunoprecipitated with 
oncogenic SF3B1K700E, we observed slightly decreased binding compared to wildtype SF3B1, and reduced HIF 
target gene expression under hypoxia (Fig. 3E-H). Gene expression analysis in patients with solid cancers 
moreover showed a consistent trend for lower expression of HIF-target genes in tumors containing SF3B1K700E 
(Suppl. Fig. 1H). 
To next investigate the importance of SF3B1-mediated HIF regulation for PDAC progression, we engineered a 
conditional Sf3b1 knockout mouse model where we reduced SF3B1 levels by heterozygous deletion of Sf3b1 (Fig. 
4A). The allele was crossed into KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Ptf1a-Cre) mice, where pancreas-
specific activation of oncogenic KrasG12D and dysfunctional Trp53 drives PDAC development within 9-14 
weeks20. As expected, homozygous deletion of Sf3b1 in the pancreas was not viable, and heterozygous deletion 
in the KPC background (KPCS) led to a significant reduction in Sf3b1 gene expression and protein levels (Fig. 
4B, Suppl. Fig. 2A, B). While no abnormalities with respect to anatomical appearance and weight of the pancreas 
were observed in Sf3b1+/- mice in the non-cancerogenic Ptf1a-Cre background (Suppl. Fig. 2C, D), in the KPC 
background heterozygous deletion of Sf3b1 led to significant morphological differences (Suppl. Fig. 2E). At 7 
weeks of age 60% of KPC mice but only 2% of the KPCS mice developed PanIN lesions (Suppl. Fig. 2F-I), and 
at 13 weeks of age 100% of KPC mice developed PanIN lesions or PDAC whereas only 60% of KPCS mice had 
grade 1 or 2 PanIN lesions (Fig. 4C, D; Suppl. Fig. 2G). Furthermore, KPC mice developed larger tumors (Suppl. 
Fig. 2J, K), and were associated with considerably shorter survival (Fig. 4F).  
While we hypothesized that heterozygous Sf3b1 deletion inhibits PDAC progression via attenuating HIF activity, 
impaired splicing could provide an alternative explanation. To discriminate between both scenarios, we 
established 3D organoid cultures from KP- and KPS animals (Fig. 4G, Suppl. Fig. 3A). This enabled us to analyze 
ductal tumor cells without stromal cell contamination21, and to control the oxygen concentration of the 
environment. We first confirmed that lentiviral transduction of a CRE recombinase induced expression of 
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KRASG12D, homozygous deletion of p53, and heterozygous deletion of Sf3b1, leading to a reduction in Sf3b1 
mRNA and protein levels (Fig. 4H; Suppl. Fig 3B-D). We next analyzed global splicing efficiencies in KPC and 
KPCS organoids under normoxic and hypoxic conditions, but did not find substantial differences in the percentage 
of ‘spliced in’ (PSI) events, including exon skips, alternative 3’and 5’ sites, and intron retentions (Fig. 4I, J; Suppl. 
Fig. 3E-L). In contrast, when we assessed the HIF pathway activity, we observed reduced expression of HIF target 
genes upon heterozygous Sf3b1 loss under hypoxia, but not under normoxia (Fig. 4K; Suppl. Fig. 3M). These 
findings were confirmed in vivo by immunohistochemistry in mouse tumors, where the expression of HIF1α as 
well as the HIF target GLUT1 was reduced in KPCS mice compared to KPC mice (Fig. 4L, M; Suppl. Fig. 3N-
Q), and in a functional assay for glycolysis, a metabolic process which is activated by hypoxia. Incubation of 
organoids with radiolabeled [14C]-2-Deoxy-D-glucose showed no major differences in glucose uptake between 
KPC and KPCS organoids under normoxic conditions (Suppl. Fig. 3R), but a decrease in glucose uptake in KPCS 
organoids under hypoxia (Fig. 4N). Supporting these results, KPCS organoids grew significantly slower than KPC 
organoids in hypoxia but not in normoxia (Fig. 4O, P).  Together, our results demonstrate that heterozygous 
deletion of Sf3b1 in PDAC does not lead to dysfunctional splicing, but impedes adaptation to hypoxia, 
highlighting the importance of the SF3B1-HIF1α axis in pancreatic cancer pathogenesis.  
Gene expression analysis in TCGA datasets, as well as knock-down experiments in melanoma- and breast cancer 
cell lines, suggest that SF3B1-dependency for HIF target gene regulation is conserved across different solid 
cancers (Fig. 1A, B; Suppl. Fig. 4A-D). This prompted us to speculate that frequent loss of heterozygosity in 
SF3B1 would only be tolerated in tumors with no or mild hypoxia. To test this hypothesis, we focused on the 
analysis of chromophobe renal cell carcinoma (chRCC), which shows an exceptional high incidence for 
heterozygous loss of SF3B1-encoding chromosome 2, manifesting in low SF3B1 expression levels compared to 
the more frequent clear cell renal carcinoma (ccRCC) and other kidney cancers22–24 (Fig. 5A). To first confirm 
that SF3B1 expression facilitates HIF signaling in chRCC, we established primary cell lines from chRCC biopsies, 
and performed a siRNA-mediated knockdown of SF3B1. Reduction in SF3B1 levels indeed led to impaired 
transcriptional response to hypoxia (Fig. 5B). After validating the high frequency of chromosome 2 loss in a 
cohort of chRCC samples (Swiss-cohort: 60% of patients - Suppl. Fig. 5A, B), we performed IHC stainings to 
assess HIF1α levels as a surrogate for HIF signaling activity. In line with our hypothesis, 90% of patient samples 
were negative for HIF1α-staining, with the remaining 10% exhibiting low levels (Fig. 5C, D). In contrast, in 
samples of clear cell renal cell carcinomas (ccRCC), a kidney cancer known for active HIF signaling22, moderate 
or high HIF1α staining was observed in 48% of samples (Fig. 5C, D). Consistent with these results, only 23% of 
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the ChRCC patients show moderate expression of the HIF target GLUT1 compared to 93% of ccRCC patients 
(Fig. 5C, D), and genes involved in oxidative phosphorylation, but not glycolysis, were upregulated in chRCC 
(Fig. 5E). These data support our hypothesis that normoxic cancers can tolerate loss of heterozygosity of SF3B1. 
They could also provide an explanation why only 4%-7% of patients of chRCC display tumor metastasis23, as for 
this process adaptation to low oxygen tension is pivotal25. Indeed, when we stratified chRCC patients with loss of 
chromosome 2 into samples with low and high SF3B1 levels (Fig. 5F; Suppl. Fig. 5C), we observed higher 
incidences of lymph node spreading (7% vs 43%) and poorer prognosis in the group with upregulated SF3B1 (Fig. 
5G, H).  
In summary, we report a novel splicing-independent role of SF3B1 in HIF signaling. Through the interaction with 
HIF1α, SF3B1 stimulates binding of the HIF1α-HIF1β heterodimer to HRE sequences, and activates 
transcription of HIF target genes. We further describe that SF3B1-dependent co-activation of HIF is relevant for 
the progression of hypoxic cancers, suggesting a causal link between high SF3B1 expression and cancer 
aggressiveness. HIF signaling regulates several hallmarks of cancer, including cell proliferation, survival, 
angiogenesis, metabolism, and tumor invasion/metastasis, and its inhibition is therefore considered to be a highly 
promising treatment approach16,26,27. Most HIF inhibitors tested in clinical trials, however, showed low specificity 
and interfered with other biological processes, leading to dose-limiting side-effects27. Since binding of SF3B1 to 
HIF1α is direct, inhibition of this interaction could sensitize tumor cells to low oxygen environments in a highly 
specific manner. Together with drugs blocking heterodimerization of HIF1α/HIF1β, such compounds might 
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METHODS 
TCGA data analysis 
TCGA RNA-seq expression and clinical data were downloaded either from the TCGA website (https://tcga-
data.nci.nih.gov), from The Human Protein Atlas29 (https://proteinatlas.org) or from The cBio Cancer Genomics 
Portal30,31 (https://cbioportal.org). For survival analysis, patients were stratified by the median of SF3B1 gene 
expression, except for the chRCC analysis. There, the upper quartile of SF3B1 expression in patients with 
chromosome 2 loss was used for stratification. In the survival analysis of chRCC patients, a missing variable 
(months) of one deceased patient in the Chr2 loss, SF3B1 high cohort was imputed by using the mean value of all 
deceased patients in the unstratified dataset. The hypoxia signature was computed as the average expression of 34 
hypoxia-inducible genes represented by CA9, NDUFA4L2, EGLN3, NDRG1, PFKFB4, ADM, NRN1, CA12, 
ENO2, ZNF395, RAB20, DDIT4, SLC7A5, BNIP3, HMOX1, POU5F1, ALDOC, PDK1, LDHA, SLC2A1, 
BNIP3L, STC2, HK2, CP, LOX, MUC1, VEGFA, SLC16A3, MXI1, GYS1, COL5A1, PPP1R3C, TXNIP, LRP1. 
K700E mutations are based on a uniform recalled variant dataset. RNA-seq data has been uniformly re-aligned 
across all 8255 cancer patient samples. Only non-alternate axons are used for gene expression quantification that 
has been quantile normalised5. Data has been made available here: https://gdc.cancer.gov/about-
data/publications/PanCanAtlas-Splicing-2018. 
Cell culture 
SK-MEL-28, PANC-1, MDA-MB-231, Mia-PaCa-2 and HEK293T cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) supplemented with 10% FBS, and 4 mM L-glutamine. AsPC-1 and BxPC-
3 cells were maintained in Roswell Park Memorial Institute (RPMI, Invitrogen) supplemented with 10% FBS and 
4 mM L-glutamine. Cell lines were cultured at 37 °C in 5% CO2. Sf9 insect cells were grown in suspension at 
27°C in Sf-900 II SFM medium (Invitrogen) supplemented with penicillin/streptomycin (Sigma-Aldrich). Cell 
density was monitored regularly and was maintained between 0.5 and 2 x106 cells/ml. All cell lines have been 
authenticated by Microsynth and regular mycoplasma tests were performed using the ScienCell Mycoplasma PCR 
detection kit (Cat. No. 8208). 
Quantitative real-time PCR analysis  
RNA was isolated using the nucleospin RNA kit (Macherey-Nagel) and reverse-transcribed to cDNA (kit: Applied 
Biosystems, ref. 43698813). SYBR-green based quantitative real-time PCR (qRT–PCR) was performed on a 
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LightCycler 480 (Roche). Ct values were normalized to the housekeeping gene TBP for human samples and to 
Actb or Ccny for the mouse samples. Primer sequences are listed in Supplementary Table 4. 
Luciferase assays 
Cells were co-transfected with a Vegf-HRE-luciferase reporter plasmid, or a Sf3b1-HRE-luciferase reporter 
plasmid together with different plasmids using lipofectamine 2000 (Invitrogen). A renilla luciferase plasmid was 
co-transfected for internal control. Cells were collected 24 hrs after transfection, and luciferase activity analyzed 
on a TECAN M1000 PRO using the dual-luciferase reporter assay system (Promega E1980). The assays were 
carried out according to the manufacturer’s instructions.  
Transient transfections  
siRNAs were transfected using Lipofectamine-RNAiMax reagent (Invitrogen). We used Qiagen human 
siSF3B1#1 (SI04159456), human siSF3B1#2 (SI04161766) and human siHIF1A 5’-CUG AUG ACC AGC AAC 
UUG A-3’ and 5’-UCA AGU UGC UGG UCA UCA G-3’. For transient overexpression studies, DNA plasmids 
were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. 
Lentivirus production and transduction 
Lentiviral particles were produced in HEK-293T cells. HEK-293T cells were purchased from American Type 
Culture Collection (ATCC). Cells were transduced with lentivirus by adding virus-containing supernatants to the 
cell culture medium. 
Chromatin immunoprecipitations (ChIP)  
ChIP assays were performed with material from HEK293T and the assays carried out using the ChIP-IT Kit 
(Active Motif) according to the manufacturer’s instructions. ChIP was performed with a HIF1a antibody from 
Abcam (ab2185), a SF3B1 antibody from MBL International (D221-3), an HIF1α antibody from Novus Biological 
(NB 100-124), or an anti-IgG antibody from Abcam (ab171870). Primer sequences used are listed in 
Supplementary Table 4. 
Immunoblotting and antibodies 
Protein lysates were resolved on polyacrylamide minigels and transferred onto nitrocellulose membrane by semi-
dry transfer. The following antibodies were used for immunoblotting: rabbit HIF1a (catalogue no. NB-100-479; 
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Novus Biologicals), mouse SF3B1 (catalogue no. D221-3; MBL International), mouse HIF1α (catalogue no. NB 
100-124; Novus Biologicals), mouse SF3B2 (catalogue no. ab56800; Abcam), rabbit SF3B4 (catalogue no. 
ab157117; Abcam), rabbit SF3B14 (catalogue no. NBP1-87431; Novus Biologicals), rabbit α-tubulin (catalogue 
no. ab18251; Abcam), rabbit CA9 (catalogue no. NB-100-417; Novus), rabbit PKM2 (catalogue no. 3198; Cell 
Signaling), rabbit PDK1 (catalogue no. 3061S; Cell Signaling), mouse HA-tag (catalogue no. 26183; Thermo 
Scientific), rabbit p53 (catalogue no. FL-393; Santa Cruz), mouse KrasG12D (catalogue no. 26036; Neweastbio), 
mouse total-Ras (catalogue no. 3965; Cell Signaling), rabbit p-Mek (catalogue no. 9154; Cell Signaling), rabbit 
total-Mek (catalogue no. 9122S; Cell Signaling), rabbit p21 (catalogue no. ab109199; Abcam), rabbit p16 
(catalogue no. ab51243; Abcam). Immunodetection and visualization of signals by chemiluminescence was 
carried out by using the ImageQuant LAS 4000 mini (GE Healthcare). For immunoprecipitation, transfected cells 
were lysed in cell lysis buffer TNN (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40, 
50 mM NaF, 1 mMDTT, 1 mM PMSF, and protease inhibitor cocktail) for 30 min. Magnetic dynabeads 
(Invitrogen) were incubated first with the primary antibody for 10 min at room temperature, washed and then 
incubated with the cell lysate for 3 hours at 4°C. The assays were carried out according to the manufacturer’s 
instructions. Finally, the beads were boiled in 2x sample buffer for 5 min and eluents were analyzed by Western 
blotting. For co-immunoprecipitation with recombinant proteins, magnetic dynabeads (Invitrogen) were incubated 
first with the primary antibody and then incubated with the recombinant proteins for 2 hours at 4°C. 
Human PDAC organoid culture 
Human PDAC organoids were established from patients’ surgical specimens and cultured as described in full 
detail by (Hirt et al, manuscript under revision). Human pancreatic tissue samples were provided by the 
Department of Pathology and Molecular Pathology, University Hospital Zurich, based on informed consent and 
study approval from the ethical committee (BASEC-Nr. 2017-01319). For all samples, the diagnosis of PDAC 
was confirmed on corresponding tissue slides reviewed by board-certified pathologists. To establish organoid 
lines, tissue was chopped and digested in full medium containing collagenase type II (5 mg/ml). The digestion 
was stopped with advanced DMEM/F12 medium supplemented with HEPES (10mM), Glutamax (1%) and 
penicillin/streptomycin (1%). Cells were seeded as 20μl drops of Matrigel (Corning, growth factor reduced) into 
a 48-well suspension culture plate. Human PDAC organoids were cultured in Advanced DMEM supplemented 
with 10 × 10−3 M HEPES, 1x Glutamax, 1% Penicillin/Streptomycin, 1x B27, 1.25 × 10−3 M N‐acetylcysteine, 
50% Wnt3a conditioned medium (CM), 10% R‐spondin‐1 CM, 10% noggin CM, 10 × 10−3 M nicotinamide, 1 × 
10−6 M prostaglandin E2, 50 ng mL−1, EGF, 10 × 10−9 M gastrin, 100 ng mL−1 FGF10 and 0.5 × 10−6 M A83‐01. 
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RCC ethics statement and patient selection 
All tissue samples were made available by the Tissue Biobank of the Department of Pathology and Molecular 
Pathology, University Hospital of Zurich, Switzerland and collected as described previously32. The local ethics 
commission approved this study (BASEC_2019-01959) and patients gave written consent. The retrospective use 
of normal and tumor tissues of RCC patients is in accordance with the Swiss Human Research Act, which allows 
the use of biomaterial and patient data for research purposes without informed consent under certain conditions 
that include the present cases (article 34). All tumors were reviewed by a board-certified pathologist and 
histologically classified according to the World Health Organization guidelines.  
ChRCC tissue processing and generation of cell models 
Renal tumors were surgically resected and underwent routine tissue processing and rapid sectioning for diagnostic 
purposes and generation of cell models (including formalin fixation and paraffin embedding, snap freezing of 
fresh tumor and normal tissue). Fresh tissue samples macroscopically identified as cancer by a pathologist with 
specialization in uropathology (H. Moch) were placed into sterile 50-ml conical tubes containing transport media 
(RPMI (Gibco, Waltham, MA) with 10 % fetal calf serum (FCS, Gibco) and Antibiotic-Antimycotic® (Gibco)) 
and stored at 4 °C until further processing. Briefly, samples were rinsed with PBS and subsequently cells were 
isolated by finely cutting the tissue into small pieces followed by collagenase A digestion for 1-3 hours at 37 °C. 
The slurry was passed through a 100 µm cell strainer to remove large fragments and the Collagenase A digestion 
was quenched with DMEM containing 10-20 % FCS. Cells were washed once with PBS and if necessary, 
erythrocytes were lysed. Finally, cell viability was evaluated by trypan blue dye exclusion and an appropriate 
number of cells was resuspended in Renal Epithelial Cell Growth Medium 2 (Promocell). This suspension was 
seeded into collagen I-coated cell culture dishes (Corning, Corning, NY) containing 30–50 % confluent 
Mitomycin C-treated mouse embryonic fibroblasts CF6 (ThermoFisher). Subsequently, the co-culture was 
maintained in Renal Epithelial Cell Growth Medium 2 in a humidified incubator at 37 °C with 5% CO2. The 
medium was replaced earliest 5 days after initial plating and subsequently every three to four days. Cells were 
expanded by passaging without the addition of new CF6 feeder cells in subsequent passages.  
 
RCC immunohistochemistry 
For immunohistochemical (IHC) analyses, a tissue microarray (TMA) and whole tissue sections of primary RCCs 
from the Department of Pathology and Molecular Pathology, University Hospital of Zurich, Switzerland were 
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used33. Clinicopathological parameters of the RCC specimens are described in Supplementary Table 3. Formalin-
fixed paraffin-embedded (FFPE) cell pellets from cell cultures were prepared as previously described34. For 
histological evaluation, FFPE specimens were sectioned (2 µm) and stained with hematoxylin and eosin (HE). 
For IHC, 2 μm sections were transferred to glass slides followed by antigen retrieval. Antibodies used for IHC 
are summarized in the table below. IHC was performed using the Ventana Benchmark automated system (Roche, 
Ventana Medical Systems, Oro Valley, AZ) and Ventana reagents. The Optiview DAB IHC detection and the 
Discovery Chromomap DAB Kits (Roche, Ventana Medical Systems) were used to stain with the antibodies 
against Glut1 and SF3B1, respectively. The staining procedure for HIF1α was carried out with the automated 
Leica BOND system using the Bond Polymer Refine Detection Kit (Leica Biosystems, Wetzlar, Germany). 
Antibody Name/Clone Dilution IHC Supplier 
SF3B1 EPR11986 1:100 Abcam 
HIF1α HIF-1 alpha antibody [mgc3] 1:400 Abcam 
GLUT1 Glucose Transporter type 1 1:1000 Millipore 
  
RNA-extraction of chRCC patient samples 
RNA extraction from FFPE specimens of chRCC was performed using the Maxwell® 16 Tissue DNA Purification 
Kit (Promega). RNA quality was assessed with the RNA Qubit™ RNA HS Assay Kit (ThermoFisher). 
Subsequently, cDNA was prepared using the Superscript IV Vilo Mastermix (Thermo Fisher). 
 
SF3B1 quantification in chRCC patient samples 
The quantitative measurements of SF3B1 were performed using the Taqman Fast Advanced master mix (Thermo 
Fisher) with 5 ng/μL ng of cDNA in each technical duplicate and the cycling parameters according to the protocol 
on a ViiA7 (Thermo Fisher). Primer and probe set assay IDs for the TaqMan assays were Hs00961640_g1 for 
SF3B1 and Hs03929097 for GAPDH, (ThermoFisher). Normal tissue was used to normalize the quantitative 
analysis of all samples. For the other genes assessed, regular qPCR was performed as described above. 
 
Analysis of Copy Number Variations (CNVs) 
DNA was processed and hybridized to Affymetrix CytoScan HD array according to manufacturer’s protocol. 
Sample level quality control was initially assessed by Affymetric ChAS software, version 2.0 and probeset.txt 
files were exported. These served as input for the rCGH R package (v. 3.8) obtained from Bioconductor. The 
comprehensive comparative genomic hybridization (CGH) analysis workflow provided by rCGH was used for 
log2 relative ratio (LRR) calculation (the sample DNA signals against a normal two-copy DNA reference), profile 
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centralization and profile segmentation. Significant focal copy number alterations were identified from segmented 
data using GISTIC 2.05. Subsequently, absolute copy numbers were inferred. 
 
Plasmid design 
Deletion mutants of HIF1a were generated by PCR using a pcDNA3-HA-HIF1a plasmid (addgene 18949) as 
template. We designed specific primers that border the domain to be deleted on both sides in order to remove the 
different targeted domains of HIF1a. 
Baculovirus expression system 
Baculovirus expression vectors expressing Strep-Tag II epitope tagged-SF3B1, HIF1α, or HIF1β were constructed 
by inserting the cDNA of corresponding genes into a pFBDM plasmid. Strep-Tag II tagged-SF3B1, HIF1α, or 
HIF1β were expressed in Sf9 cells that had been infected with recombinant baculovirus as described in the Bac-
to-Bac® Baculovirus Expression System from Invitrogen. 
Co-immunoprecipitation assays 
Transfected cells were lysed in cell lysis buffer TNN (50mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 
0.5% NP-40, 50 mM NaF, 1 mM DTT, 1 mm PMSF, and protease inhibitor cocktail) for 30 min. Magnetic 
dynabeads (Invitrogen) were incubated first with the primary antibody for 10 min at room temperature, washed 
and then incubated with the cell lysate for 3 hours at 4°C. The assays were carried according to the manufacturer’s 
instructions. Finally, the beads were boiled in 2x sample buffer for 5 min. The eluents were analyzed by Western 
blotting. For co-immunoprecipitations with recombinant proteins, magnetic dynabeads (Invitrogen) were 
incubated first with the primary antibody, then incubated with the recombinant proteins for 2 hours at 4°C. 
Mouse strains 
LSL-KrasG12D/+; LSL-Trp53R172H (KP), and LSL-KrasG12D/+; LSL-Trp53R172H/+; Ptf1a-Cre (KPC) were obtained 
from Tyler Jack’s (Howard Hughes Medical Institute). Sf3b1 flox/flox mice were generated by targeting exon 
five and six of the Sf3b1 gene. These exons were floxed with LoxP sites and the targeted region was about 3.0 
kb. A LoxP/FRT-flanked neomycin resistance cassette was placed 277 bp upstream of exon five and six for 
selection. Chimeric mice were generated via electroporation in embryonic stem cells followed by microinjection 
in blastocysts and implantation into foster mice. For all in vivo experiments, except the survival experiment, mice 
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between the age of 7 and 13 weeks were used. Female and male mice were used for all experiments. All mice 
were maintained in a SPF animal facility at the ETH Phenomics Center EPIC at ETH Zürich. Maintenance and 
animal experiments were conducted in accordance with the Swiss Federal Veterinary Office (BVET) guidelines. 
Animal surgeries and ultrasound (Vevo 2100 system) analysis was performed blinded by a veterinarian. Animal 
numbers for experiments were chosen based on expected mortality rates and phenotypical changes of the pancreas 
in mice.  
Histological and immunohistochemical analysis (murine specimen) 
Following euthanasia, pancreata were removed, weighed and fixed overnight in 10% neutral buffered formalin 
(Formafix Switzerland AG, Hittnau, Switzerland). The tissue was embedded in paraffin and cut serially into 3-5-
μm sections, which were stained with hematoxylin and eosin (HE) and Masson trichrome for the assessment of 
fibrosis. Histological analysis, including murine pancreatic intraepithelial neoplasia (mPanIN) grading and 
assessment of the proportion of affected versus unremarkable pancreatic parenchyma, was carried out in the HE-
stained sections in a blinded fashion by an ECVP-board certified veterinary pathologist (GP), according to 
previously reported criteria35. Immunohistochemistry (IHC) was conducted on consecutive paraffin-embedded 
sections using the primary antibodies against HIF1α (rabbit polyclonal, Novus Biological, NB100-479, 1:500), 
SF3B1 (rabbit monoclonal, clone number EPR11986, Abcam, ab172634, 1:100), GLUT-1 (rabbit polyclonal, 
Merck Millipore, #400060, 1:100), Ki-67 (rabbit monoclonal, clone name 30-9, Ventana Roche, 790-4286, 
1:400), cleaved caspase 3 (rabbit monoclonal, clone number D3E9, Cell Signaling, Cell Signaling, #9579, 1:400) 
and CD31 (rabbit polyclonal, Santa Cruz, sc-1506R, 1:1000). All immunostains were performed in Ventana 
Discovery (Ki-67 and cleaved caspase 3) or Dako autostainers using 3,3’ diaminobenzidine (DAB) chromogen 
(Dako-Agilent Technologies, Denmark). All slides were scanned using digital slide scanner NanoZoomer-XR 
C12000 (Hamamatsu, Japan) and images were taken using NDP.view2 viewing software (Hamamatsu). mPanIN 
were counted manually in 10 high power fields (HPF) in each HE-stained section. Automated quantitative analysis 
was carried out on the digital slides using the Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, 
Hørsholm, Denmark). Briefly, a linear threshold classification allowed recognition of the blue (Masson trichrome) 
or DAB brown (IHC) structures in 20 regions of interest (ROI) sized 0.237 mm2 (the area of an HPF with one 
ocular of 22 mm field of view), randomly selected across the pancreatic parenchyma. Results were expressed as 
percentage of positive area/ROI vs total parenchyma/ROI (Masson trichrome, HIF-1a, GLUT1, CD31) or average 
number of positive nuclei or cells/ROI (SF3B1, Ki-67, cleaved caspase 3). 
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Heterozygous knockout of SF3B1 by CRISPR-Cas9 
We used the sgRNA-Designer platform by the Broad Institute to design sgRNAs for targeted gene knock-out 
(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgRNA-design). Two distinct sgRNAs were used: 
sgSF3B1_A (5’-TAATCTTCATCAATCAATAG-3’) and sgSF3B1_B (5’-AAGATCGCCAAGACTCACGA-
3’). According to the protocol from Shalem et al., we adapted the sgRNA design for subsequent cloning into the 
LentiCRISPRv2 backbone36. Cells were transduced with lentivirus and selected with puromycin. Heterozygous 
knock-out of the target gene was validated with deep sequencing for PANC-1 and AsPC-1 cells at two distinct 
time-points, to assess the enrichment of in-frame indels. Primers were designed flanking the predicted sgRNA 
cut-site and containing primer binding sites for Illumina TruSeq Deep sequencing primers. After purification, the 
amplicons were sequenced on an Illumina MiSeq System, with a minimum of 5’000 reads. Analysis of editing 
events was performed with CRISPResso V1.0.1.  
Murine pancreatic ductal organoid culture 
Pancreatic ducts were isolated from the whole organ of 13 weeks old KP and KPS mice as previously described37. 
Each organoid line was isolated from an individual mouse. Isolated ducts as well as the ensuing organoids were 
embedded in growth-factor reduced (GFR)-Matrigel (Corning), and cultured in organoid medium (OM), which is 
composed of AdDMEM/F12 (Gibco) supplemented with GlutaMAX (Gibco), HEPES (Gibco), Penicillin-
Streptomycin (Invitrogen), B27 (Gibco), N-2 (Gibco), 1.25 mM N-Acetyl-L-cysteine (Sigma), 10 nM Gastrin I 
(Sigma) and the growth factors: 100 ng/ml FGF10 (Peprotech), 50 ng/ml EGF (Peprotech), 100 ng/ml Noggin, 
100 ng/ml RSPO-1 (Peprotech), and 10 mM Nicotinamide (Sigma). For the first week after duct isolation the 
culture medium was supplemented with 100 µg/ml Primocin (InvivoGen).  
Lentiviral production and transduction of organoids 
The plasmids FUG-T2A-GFP-Cre and control GFP were purchased from Addgene #66691 and lentiviral particles 
were produced in HEK-293T cells using X-tremeGene 9 DNA Transfection Reagent (Roche). Upon 
ultracentrifugation concentrated virus particles were stored at -80°C and used to infect pancreatic ductal organoid 
cultures as previously described37. Briefly, upon dissociation of the GFR-Matrigel, organoid cultures were broken 
down into single cells using TrypLE Express (Gibco) and fire-polished glass Pasteur pipettes. Single cells were 
transferred to maximum recovery microtubes (Axygen) and centrifuged at 800 g for 5 min at 4°C. The pellets 
were resuspended in 250 µl OM and inoculated with 10 µl of concentrated virus particles that was then incubated 
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at 37°C for 4-6 h. After a washing step, the cells were seeded in GFR-Matrigel and grown in OM. Two to three 
weeks later the pool of GFP-expressing organoids was dissociated again into single cells and subjected to FACS 
analysis (MoFlo® Astrios™ EQ) to sort for GFP-positive cells. The cells were put back into culture and used for 
subsequent experiments.  
Organoid proliferation assay 
Organoids were seeded as single cells at a density of 500 cells/μl GFR-Matrigel (Corning). 48 hours after seeding, 
cells were exposed to 1% O2 in a hypoxia chamber (SCI-tive Hypoxia Workstation, Baker Ruskinn) or kept in a 
cell culture incubator at 21% O2. At depicted time-points, the organoids were recovered from the matrigel and 
dissolved in 200 μl TE-buffer. After 3 freeze-thaw cycles, the amount of DNA was quantified with Quant-iT™ 
PicoGreen™ dsDNA Assay Kit (ThermoFisher Scientific) according to the manufacturer’s instructions. Absolute 
values were normalized to the DNA-content 48 hours after seeding. 
[14C] 2-Deoxy-D-glucose uptake 
For organoid experiments, 3 wells of 50 µl matrigel-embedded organoids per condition were seeded in a 24-well 
plate. On day 3, cells were kept in normoxia or exposed to hypoxia (at 1% O2) for 12 hours. The medium was 
replaced with DMEM containing uniformly-labelled [14C] 2-Deoxy-D-glucose (Hartmann Analytic) at a 
concentration of 150 μci/mmol and 5 mM glucose. Cells were washed twice with PBS just before harvesting. 
Radioactivity counts were normalized to cell number.  
Illumina RNA sequencing experiment  
Multiple organoid lines (5x KPC, 4x KPCS) were seeded as described, where each line was derived from an 
individual mouse. After 48 hours of exposure to 1% O2 or 21% O2, organoids were harvested and RNA was 
extracted using the NucleoSpin® RNA kit (Macherey-Nagel) according to the manufacturer’s instructions. For 
each organoid line, 2-3 wells of organoids from a 24 well plate were harvested in lysis buffer RA1 (RNA 
extraction kit, MN) supplemented with TCEP (Tris(2-carboxyethyl)phosphine hydrochloride). For library 
preparation, the quantity and quality of the isolated RNA was determined with a Qubit® (1.0) Fluorometer (Life 
Technologies, California, USA) and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). The TruSeq Stranded 
mRNA Sample Prep Kit (Illumina, Inc, California, USA) was used in the succeeding steps. Briefly, total RNA 
samples (1 μg) were ribosome depleted and then reverse-transcribed into double-stranded cDNA with 
Actinomycin added during first-strand synthesis. The cDNA samples were fragmented, end-repaired and 
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polyadenylated before ligation of TruSeq adapters. The adapters contain the index for multiplexing. Fragments 
containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and quantity of the 
enriched libraries were validated using Qubit® (1.0) Fluorometer and the Bioanalyzer 2100 (Agilent, Waldbronn, 
Germany). The product is a smear with an average fragment size of approximately 360 bp. The libraries were 
normalized to 10nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20. Cluster generation and sequencing involved 
application of the TruSeq SR Cluster Kit v4-cBot-HS or TruSeq PE Cluster Kit v4-cBot-HS (Illumina, Inc, 
California, USA) using 8 pM of pooled normalized libraries on the cBOT. Sequencing were performed on the 
Illumina HiSeq 4000 paired end at 2x 100 bp (2x at least 40 million reads) using the TruSeq SBS Kit v4-HS 
(Illumina, Inc, California, USA).  
RNAseq data analysis 
The fastq data for the read pairs from the Illumina sequencer has been processed in a bioinformatic workflow. 
First, the remains of the adapters and sub-standard quality reads have been trimmed with trimmomatic (v0.35). 
For the pairs in which both reads have passed the trimming, they have been mapped to the mm10 mouse genome 
using STAR (v2.7.0a) and indexed BAM files obtained with samtools (v1.9). The reads have been counted using 
featureCounts from subread package (v1.5.0) with the options for pairs of reads to be counted as RNA fragments. 
The counting used Ensembl v95 mouse genome annotation GTF file. The count vectors for all the samples have 
been combined into a count table. The table has been processed in the secondary (statistical) analysis with R 
scripts using edgeR (v3.24.3), in particular binomial generalized log-linear model with contrast tests. It resulted 
in lists of genes ranked for differential expression by p-value and used Benjamini-Hochberg adjusted p-value as 
the estimate of the false discovery rate. Read counts are listed in Supplementary Table 1. 
Splicing analysis 
All splice events were identified using SplAdder on the aligned RNA-Seq BAM files28. Gencode release M20 
(Mus_musculus.GRCm38.95) was used for identification of slice events. Splice events considered were exon 
skips, alternative 3’/5’, and intron retentions. Only events with highest confidence as defined by SplAdder (level 
3) were considered for downstream analyses. All parameters used for the analyses are listed here: 
-v y -M merge_graphs -t exon_skip,intron_retention,alt_3prime,alt_5prime -c 3 --ignore_mismatches y 
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 Only events with a minimum of 5 reads and an average expression greater than 20 reads in the flanking exons 
across all samples were considered in the analysis. All plots and analyses performed on SplAdder output were 
done in R (version 3.3.3).  Intron retention events are listed in Supplementary Table 2. 
Statistical analysis 
Statistical significance was determined using the statistical tests indicated in the respective figure legends. Data 
are presented as mean ± SD, if not indicated differently. Mouse studies were not randomized, but were blinded as 
the analyses were conducted on randomly assigned mouse number, and given to operators without any information 
until the end of the experiments. Animals of both genders were used and mice with health concerns were excluded 
from experiments. No inclusion/exclusion criteria were pre-established. No statistical methods were used to 
predetermine sample size. All experiments are performed at least 3 times if not indicated differently; n refers to 
the number of biological replicates. 
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Figure 1. SF3B1 is required for efficient HIF signalling. (A and B) Scatter plot showing the correlation of 
SF3B1 and HIF1A (A) and HIF1B (B) expression in PDAC, prostate cancer (PCA), hepatocellular carcinoma 
(HCC) and breast cancer (BRCA). The significance of the correlation in is indicated by its p-value. (C) Survival 
of patients was stratified according to the median SF3B1 expression in the indicated cancer types. P-values were 
computed with a Log-rank (Mantel-Cox) test. (D) Scatter plot showing the correlation between SF3B1 mRNA 
levels and a hypoxia signature in PDAC patients, which is represented by the mean expression value (TPM) of 34 
HIF-target genes. (E) SF3B1 expression in a panel of human patient-derived PDAC organoids exposed to 1% O2 
for 12 hours. Error bars indicate standard deviation (S.D.) of biological replicates. Two-tailed unpaired t-test was 
used to compute the indicated p-values. (F) Transfection of a wildtype (WT) or HRE-mutated SF3B1 promoter-
luciferase reporter together with either an empty vector control, or HIF1α∆∆P in AsPC-1 cells. Data are shown as 
mean ± S.D. of biological replicates (n=3). ** P<0.01 normalized to mock wtHRE, two-tailed unpaired t-test. (G 
and H) Transfection of a VEGF promoter-luciferase reporter alone or together with either HIF1α∆∆P (the 
constitutively active form of HIF1α), or in combination with different concentrations of SF3B1 plasmid in PANC-
1 (G) and AsPC-1 cells (H). Data are shown as mean ± S.D. of biological replicates (n=3). *<P0.05, **P<0.01, 
***P<0.001. One-way ANOVA followed by a Dunnet’s multiple comparison post-test. (I) Heatmap showing the 
expression of various HIF1α-target genes in patient-derived PDAC organoid lines and commercial PDAC cell 
lines after overexpression or knockdown of SF3B1, either with CRISPR-Cas9 or siRNA. The indicated fold-
changes are relative to the following controls: Transfection with an empty-vector (overexpression), the respective 
unedited cell line (CRISPR-hetloss) or treatment with control siRNA (knockdown). Expression levels are relative 
to the housekeeping gene TBP. For PANC-1, usage of two distinct guide RNAs are indicated by subscripted a and 
b.  For each cell line and its respective control, the experiment was performed at least three times.  
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Figure 2. SF3B1 physically interacts with HIF1α.  (A) Protein extracts from HEK293T cells exposed to 21% 
or 1% O2 for 12 hours were subjected to immunoprecipitation (IP) with an anti-SF3B1 antibody or anti-mouse 
IgG and processed for immunoblotting for indicated proteins. (B) Protein extracts from HEK293T cells exposed 
to 21% or 1% O2 for 12 hours were subjected to IP with an anti-HIF1β antibody or anti-mouse IgG and processed 
for immunoblotting for indicated proteins. (C) Protein extracts from HEK293T cells transfected with the indicated 
siRNAs, exposed to 1% O2 for 12 hours, were subjected to IP with an anti-HIF1α antibody or anti-rabbit IgG and 
processed for immunoblotting for indicated proteins. (D) Protein extracts from HEK293T cells transfected with 
the indicated siRNAs, exposed to 1% O2 for 12 hours, were subjected to IP with an anti-HIF1β antibody or anti-
rabbit IgG and processed for immunoblotting for indicated proteins. (E) Recombinant strep-tagged HIF1α, SF3B1 
and HIF1β proteins purified from Sf9 insect cells were mixed and subjected to IP using an anti-HIF1α antibody 
or anti-rabbit IgG as control and processed for immunoblotting for indicated proteins. (+) means that the indicated 
recombinant protein was added to the IP, (-) means that the indicated recombinant protein was omitted from the 
IP. (F) Recombinant strep-tagged HIF1α, SF3B1 and HIF1β proteins were subjected to IP using an anti-SF3B1 
antibody or anti-mouse IgG as control and processed for immunoblotting for indicated proteins. (+) means that 
the recombinant protein was added to the IP, (-) means that the recombinant protein was omitted from the IP. (G) 
Schematic of full-length HIF1α and corresponding deletion mutants (numbered 1-6) used in IP experiments with 
an anti-SF3B1 antibody. (+) and (-) signs denote SF3B1 binding (experimental data are displayed in Fig. 2H). 
bHLH: basic helix-loop-helix, PAS-A and PAS-B: Per-ARNT-Sim domains, ODD: oxygen-dependent 
degradation domain and TAD: transactivation domain. (H) HEK293T cells were transfected with a HA-tagged 
WT full length (FL) or mutant forms of HIF1α (1-6).  Lysates were then processed for immunoprecipitation with 
an anti-HA antibody (HA-IP) followed by immunoblotting with an anti-HA antibody.  (I) Protein extracts from 
HEK293T cells exposed to 1% O2 for 8 hours were subjected to IP, with an anti-SF3B1 antibody or an anti-mouse 
IgG (left), or with an anti-HIF1α antibody and an anti-rabbit IgG (right). All samples were processed for 
immunoblotting for indicated proteins. The arrow on the right indicates the IgG band.  
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Figure 3. SF3B1 increases binding of HIF1α to its target genes. (A and B) Chromatin immunoprecipitation 
(ChIP) using a specific antibody against SF3B1 in HEK293T cells. (A) Cells are cultured under 21% or 1% O2 
for 8 hours. The fold-increase in target gene binding under hypoxia is shown relative to normoxia. (B) Cells are 
transfected with siRNA targeting HIF1α or scrambled siRNA, and incubated in 1% O2 for 8 hours. The decrease 
in target gene binding in HIF1α-siRNA treated cells is shown relative to the control.  (C and D) Chromatin 
immunoprecipitation (ChIP) using a specific antibody against HIF1α in HEK293T cells. (C) Cells are cultured 
under 21% or 1% O2 for 8 hours, the fold-increase in hypoxia is shown relative to normoxia. (D) Cells are 
transfected with siRNA targeting SF3B1 or scrambled siRNA, and incubated in 1% O2 for 8 hours. The decrease 
in target gene binding in SF3B1-siRNA treated cells is shown relative to the control. (A – D) Results show three 
independent experiments. (E) Representative Western-blot of the Co-IP of HA-tagged HIF1α and FLAG-tagged 
wildtype SF3B1, and its variant K700E. (F) Quantification of HA-tagged HIF1α in HEK293T cells, pulled down 
with the indicated SF3B1 variants. The data are represented as mean ± S.D. of independent experiments (n = 7). 
P-value was calculated by a two-tailed unpaired t-test. (G) Transfection of the indicated constructs in HEK293T 
cells stably expressing a HIF-luciferase reporter. Data are shown as mean ± S.D. of biological replicates, indicated 
by data points. *<P0.05, **P<0.01, ***P<0.001, two-tailed unpaired t-test. Data are normalized to transfection of 
an empty vector construct. (H) qPCR analysis of HIF-target genes in the indicated cell lines overexpressing 
SF3B1K700E after exposure to 1% O2 for 8 hours. Data are normalized to the respective cell lines overexpressing 
wildtype SF3B1 after exposure to 1% O2 for 8 hours. Expression levels are relative to the housekeeping gene TBP 
(n = 2-3). Each data point represents an individual experiment of the depicted cell line. * P<0.05, ** P<0.01, *** 
P<0.001, two-tailed unpaired t-test. 
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Figure 4. Heterozygosity of Sf3b1 hampers PDAC progression through impaired HIF-signalling. (A) 
Schematic representation of the transgenic approach to obtain pancreas-specific heterozygosity of Sf3b1. (B) 
qPCR analysis of Sf3b1 mRNAs from pancreata of KP, KPC and KPCS mice of 13 weeks of age. For *P<0.05 
**P<0.01. One-way ANOVA followed by a Tukey’s multiple comparison post-test.  (C) Representative images 
of H&E staining and Masson’s Trichrome staining showing histopathologic lesions in pancreata of KP, KPC and 
KPCS mice at 13 weeks of age. Dashed lines indicate the area magnified below. Scale bar is 100 µm. (D) 
Quantification of the prevalence of mPanIN and PDAC in the H&E-stained pancreatic sections of 13-week-old 
KP, KPC and KPCS mice. Ten high power fields (HPF) were analysed per animal. Data are represented as mean 
± S.D. (n = 5). * P<0.05, ** P<0.01, *** P<0.001. One-way ANOVA followed by a Tukey’s multiple comparison 
post-test. (E) Pancreas weight of 13 weeks old KP, KPC and KPCS mice. The data are represented as mean ± 
S.D. (n = 6-7). ** P<0.01, **** P<0.0001.  One-way ANOVA followed by a Tukey’s multiple comparison post-
test.  (F) Kaplan-Meier survival curve of KP, KPC and KPCS mice over time (KP n = 8, KPC n = 10, KPCS n = 
10). Long rank test. (G) Schematic representation of the generation of murine tumor organoids with GFP or GFP-
Cre viruses derived from KP and KPS mice. Expression of Cre recombinase in KPC and KPCS organoids leads 
to the activation of KrasG12D and Trp53R17H and to a loss of one allele of Sf3b1 in KPCS organoids. (H) Protein 
extracts from KP, KPC, KPS, and KPCS organoids grown under normoxic conditions were immunoblotted for 
the indicated proteins.  (I and J) Scatter plot of percent spliced-in (PSI) events in KPC and KPCS organoids 
cultured in normoxia (G) and hypoxia (H), representing a measure of high confidence alternative splice events (n 
≥ 4 organoid lines, lines established from individual mice). (K) Expression levels of HIF1α target genes 
determined by qPCR of KPC and KPCS organoids (n = 6 organoid lines) cultured in normoxia and hypoxia for 
48 hours. Expression levels are relative to the housekeeping gene Actb. Data are shown as mean ± SEM. For each 
organoid line, the experiment was performed in three biological replicates. * P<0.05, One-way ANOVA followed 
by a Tukey’s multiple comparison post-test. (L and M), Quantification of HIF1α (L) or GLUT1 (M) positive 
areas in KP, KPC and KPCS mice at 13 weeks of age. Ten high power fields (HPF) were analysed per animal (n 
= 5). * P<0.05. One-way ANOVA followed by a Tukey’s multiple comparison post-test. (N) KPC and KPCS 
organoids were incubated in medium containing [14C] 2-deoxyglucose at different time-points and processed for 
glucose uptake measurements. Organoids were exposed to 1% O2 for 12 hours. Counts were normalized to the 
cell number (n = 4 biological replicates per time point and condition). ** P<0.01, One-way ANOVA followed by 
a Tukey’s multiple comparison post-test. (O and P) Proliferation of organoids in normoxia (O) and hypoxia (P). 
Data are shown as mean ± SEM of organoid lines (n ≥ 6 organoid lines). For each organoid line, the experiment 
was performed in three biological replicates. ** P<0.01, indicating comparison of KPC and KPCS, Two-way 
ANOVA followed by a Sidak’s multiple comparisons test. 
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Figure 5. ChRCC with heterozygous SF3B1 loss grows in a normoxic environment. (A) Expression of SF3B1 
and loss of heterozygosity (LOH) in clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell 
carcinoma (chRCC) based on TCGA data. One-way ANOVA followed by a Tukey’s multiple comparison post-
test. (B) qPCR analysis of indicated genes in patient-derived cell chRCC cells treated with siControl or siSF3B1 
under 1% O2 for 8 hours. Data represents results of three independent experiments. Expression levels are relative 
to the housekeeping gene TBP.  * P<0.05, *** P<0.001, two-tailed unpaired t-test. (C) Representative H&E and 
IHC staining of HIF1α and GLUT1 of ccRCC and chRCC patients, scale bar is 50µm. (D) Quantification of HIF1α 
and GLUT1 staining in ccRCC and chRCC patients, categorized as intense (2), weak (1) or no detectable (0) 
staining. (E) qPCR analysis of genes involved in glycolysis and oxidative phosphorylation in chRCC tumors (n = 
18) and matched kidney tissue (n = 18). Expression levels are relative to TBP.  * P<0.05, ** P<0.01, *** P<0.001, 
two-tailed unpaired t-test. (F) Relative SF3B1 expression of the stratified TCGA-cohort. *** P<0.001, **** 
P<0.0001. One-way ANOVA followed by a Tukey’s multiple comparison post-test. (G) Survival of patients 
(TCGA cohort) stratified according to chromosome 2 status and SF3B1 expression as indicated. P-value was 
computed with a Log-rank (Mantel-Cox) test. (H) Percentage of chRCC patients (TCGA cohort) where spreading 
to lymph nodes was observed. Patients lacking information of lymph node status were omitted for analysis. 
Significance was computed with chi-square tests.   
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Supplementary Figure 1. Effects of SF3B1 reduction on HIF-response. (A) Relative SF3B1expression in the 
indicated patient-derived organoids and cell lines, engineered with CRISPR-Cas9 (mono-allelic loss of SF3B1) 
or treated with siRNA, and measured by qPCR. In PANC-1 cells, two different guide RNAs were used to target 
SF3B1. Data are shown as mean ± S.D. of biological replicates (n = 3). The data is normalized to the respective 
unedited cell line (CRISPR-Hetloss) or treatment with control siRNA. Expression levels are relative to TBP. (B) 
Western blot analysis for FLAG in protein extracts from PANC-1 cells overexpressing FLAG-tagged SF3B1. (C) 
Intron retention assessed by qPCR; expression levels are relative to the housekeeping gene TBP. Data are shown 
as mean ± S.D. of biological replicates (n ≥ 3). (D and E) Protein extracts from HEK293T cells treated with 
siRNA targeting SF3B1 (D) or HIF1α (E), exposed to 21% or 1% O2 for 12 hours and processed for 
immunoblotting for the indicated proteins. (F) Chromatin immunoprecipitation (ChIP) from HEK293T cells 
cultured under 21% or 1% O2 for 8 hours using a specific antibody against HIF1β. The fold-increase in hypoxia 
is shown relative to normoxia. (G) Cells were transfected with siRNA targeting SF3B1 or scrambled siRNA, and 
incubated in 1% O2 for 8 hours. The decrease in target gene binding in SF3B1-siRNA treated cells is shown 
relative to the control. (F, G) Results show three independent experiments. (H) Pan-cancer analysis of selected 
HIF-target genes in patient samples with SF3B1K700E or SF3B1-WT (reference).  Only solid cancers in the TCGA 
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Supplementary Figure 2
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Supplementary Figure 2. Effect of SF3B1 reduction on PDAC growth. (A) Representative 
immunohistochemical staining for SF3B1 in pancreata from 7- and 13-week old KP, KPC and KPCS mice. 
Dashed lines indicate the area magnified below. Scale bar is 100 µm. (B) Quantification of SF3B1 positive areas 
in KP, KPC and KPCS mice at 7 and 13 weeks of age. Ten high power fields (HPF) were analysed per animal (n 
= 5). * P<0.05. One-way ANOVA followed by a Tukey’s multiple comparison post-test. (C) H&E staining of 
pancreata from Sf3b1fl/+ and Sf3b1fl/+; Ptf1aCre mice at 13 weeks of age. Representative images, scale bar is 100 
µM. (D) Evaluation of pancreas weight of Sf3b1fl/+ and Sf3b1fl/+; Ptf1aCre, mice at 13 weeks of age. The data are 
represented as mean ± S.D. (n = 6-7). (E) Representative photographs of KP, KPC, and KPCS pancreata from 13 
weeks-old mice. Scale bar: 1cm. (F) Representative images of H&E staining revealing the histopathologic lesions 
in pancreata of KP, KPC and KPCS mice at the indicated age. Square dashed lines indicate the area magnified in 
the image below. Scale bar is 100 µm. (G – I) Quantification of the prevalence of mPanIN and PDAC in the H&E-
stained pancreatic sections of 7-week-old KP, KPC and KPCS mice (G). Quantification of the affected pancreas 
at the indicated age (H, I). Ten high power fields (HPF) were analysed per animal. The data are represented as 
mean ± S.D. (n = 5). * P<0.05, ** P<0.01, *** P<0.001. One-way ANOVA followed by a Tukey’s multiple 
comparison post-test. (J) Pancreas weight of KP, KPC and KPCS mice at 7 weeks of age. The data are represented 
as mean ± S.D. (n = 6-7). * P<0.05, ** P<0.01, *** P<0.001. One-way ANOVA followed by a Tukey’s multiple 
comparison post-test. (K) Body weight of KP, KPC, and KPCS mice at indicated time point over a period of 13 
weeks. The data are normalized to body weight of the mice at 5 weeks of age and represented as mean ± S.D. (n 
= 6-8).  * P<0.05, ** P<0.01. One-way ANOVA followed by a Tukey’s multiple comparison post-test. 
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Supplementary Figure 3. Sf3b1 heterozygosity affects PDAC growth via HIF signalling. (A) Bright field and 
fluorescence images of mouse organoids transduced with a GFP-Cre virus after FACS. (B) Representative PCR 
analysis of genomic DNA from KP, KPC, KPS and KPCS organoids. The Cre-mediated recombination of the 
conditional allele KrasG12D/+, Trp53R172H/+ generates a single LoxP site and 2 LoxP sites for Sf3b1. (C) Sf3b1 
DNA levels at exon 5 for validation of monoallelic Sf3b1 knockout in the indicated organoid lines assessed by 
qPCR. Values were normalized to Sf3b1 exon 2 DNA levels, which remain unaffected by Cre-lox recombination. 
(D) Sf3b1 mRNA expression of KPC and KPCS organoid lines. *P<0.05, ** P<0.01, two-tailed unpaired t-test. 
(E-L) Scatter plot of alternative 3’ end usage (E, I), intron retention (F, J), alternative 5’ end usage (G, K) and 
exon skipping (H, L) events in KPC and KPCS organoids cultured in normoxia (E to H) and hypoxia (I to L).  
Events were computed by SplAdder29, only high confidence events were considered for the analyses. (M) 
Heatmap displaying normalized read counts for the indicated genes derived by RNA-sequencing. (N) 
Representative immunohistochemical staining for GLUT1 in pancreata from 7-week and 13-week old KP, KPC 
and KPCS mice. Dashed lines indicate the area magnified below. Scale bar: 100 µm. (O) Representative 
immunohistochemical staining for HIF1α in pancreata from 7-week and 13-week old KP, KPC and KPCS mice. 
Dashed lines indicate the area magnified below. Scale bar: 100 µm. (P) Quantification of GLUT1 positive areas 
in KP, KPC and KPCS mice at 7 weeks of age. Ten high power fields (HPF) were analysed per animal (n = 5). * 
P<0.05. One-way ANOVA followed by a Tukey’s multiple comparison post-test. (Q) Quantification of HIF1α 
positive areas in KP, KPC and KPCS mice at 7 weeks of age. Ten high power fields (HPF) were analysed per 
animal (n = 5). * P<0.05. One-way ANOVA followed by a Tukey’s multiple comparison post-test. (R) KPC and 
KPCS organoids were incubated in normoxic conditions in medium containing [14C]-2-deoxyglucose at different 
time-points and processed for glucose uptake measurements. Counts were normalized to the cell number (n = 4 





preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 







































HIF1  P + SF3B1 200ng
HIF1  P + SF3B1 300ng

























HIF1  P 
HIF1  P + SF3B1 200ng
HIF1  P + SF3B1 300ng

























































21% O2 siSF3B1 #1
21% O2 siSF3B1 #2
1% O2 siCTRL
1% O2 siSF3B1 #1













































21% O2 siSF3B1 #1
21% O2 siSF3B1 #2
1% O2 siCTRL
1% O2 siSF3B1 #1
1% O2 siSF3B1 #2
MDA-MB-231
# # # #
*** ****
# # # #
**** ****





# # # #
****
****
# # # #
****
# # # ** **
# # # #
****
****
# # # #
***
****
# # # # ** **
# # # #
****
****
# # # #
****
****
# # # #
****
****
















preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.10.376780doi: bioRxiv preprint 
Supplementary Figure 4. SF3B1 reduction affects HIF signalling in various cancer cell lines. (A and B) 
qPCR analyses of the indicated genes in SK-MEL-28 (A) and MDA-MB-231 (B), transfected with the depicted 
siRNAs and incubated in 21% or 1% O2 for 12 hours. Expression levels are relative to TBP. Data are shown as 
mean ± S.D. of biological replicates (n=3). *P<0.05, **P<0.01, ****P<0.0001, data normalized to 1% O2 siCTRL. 
For # P<0.05, ## P<0.01, #### P<0.0001, data are normalized to 21% O2 siCTRL. Two-tailed unpaired t-test. (C 
and D) Transfection of a VEGF promoter-luciferase reporter alone or together with either HIF1α∆∆P (the 
constitutively active form of HIF1α), or in combination with different concentrations of SF3B1 plasmid in SK-
MEL-28 (C) and MDA-MB-231 cells (D). Data are shown as mean ± S.D. of biological replicates (n = 3). *<P0.05, 
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Supplementary Figure 5. SF3B1 heterozygosity is frequently observed in chRCC. (A) Copy number 
variations (CNV) analysed with array-based comparative genome hybridization (array-CGH) of tumors from 11 
chRCC patients of the Swiss-cohort. (B) Chromosome 2 status in chRCC samples of the TCGA cohort and the 
Swiss cohort. The Swiss cohort is composed of samples published by Ohashi et al.24 (n=24) and the samples 
shown in Suppl. Fig. 5A (n=11). (C) Representative H&E and IHC staining of SF3B1 chRCC patients without 
loss (left) and with loss (middle and right) of chromosome 2. The middle staining shows compensation of 
heterozygous loss of SF3B1, whereas the sample on the right has reduced levels of SF3B1. Scale bar is 50µm. 
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